ATE416784T1 - Verfahren zur herstellung einer zubereitung mit einer bioaktiven substanz - Google Patents

Verfahren zur herstellung einer zubereitung mit einer bioaktiven substanz

Info

Publication number
ATE416784T1
ATE416784T1 AT01998183T AT01998183T ATE416784T1 AT E416784 T1 ATE416784 T1 AT E416784T1 AT 01998183 T AT01998183 T AT 01998183T AT 01998183 T AT01998183 T AT 01998183T AT E416784 T1 ATE416784 T1 AT E416784T1
Authority
AT
Austria
Prior art keywords
bioactive substance
preparation
producing
solid material
amount
Prior art date
Application number
AT01998183T
Other languages
English (en)
Inventor
Yoshihiro Ohmachi
Masafumi Misaki
Shigeyuki Takada
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Application granted granted Critical
Publication of ATE416784T1 publication Critical patent/ATE416784T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5089—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT01998183T 2000-12-01 2001-11-29 Verfahren zur herstellung einer zubereitung mit einer bioaktiven substanz ATE416784T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2000367183 2000-12-01

Publications (1)

Publication Number Publication Date
ATE416784T1 true ATE416784T1 (de) 2008-12-15

Family

ID=18837665

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01998183T ATE416784T1 (de) 2000-12-01 2001-11-29 Verfahren zur herstellung einer zubereitung mit einer bioaktiven substanz

Country Status (8)

Country Link
US (2) US7090869B2 (de)
EP (2) EP1346722B1 (de)
JP (1) JP2009062389A (de)
AT (1) ATE416784T1 (de)
AU (1) AU2002224124A1 (de)
CA (1) CA2430934C (de)
DE (1) DE60136958D1 (de)
WO (1) WO2002043709A1 (de)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10353856A1 (de) * 2003-11-18 2005-06-16 Goldschmidt Ag Emulgatorfreie Öl in Wasser-Emulsionen von Organopolysiloxanen und deren Verwendung in technischen Anwendungen
EP1586310B1 (de) * 2004-04-15 2006-12-27 Helm AG Verfahren zur Herstellung von freifliessenden, pulverförmigen Valsartan-Adsorbaten
CA2568640C (en) 2004-06-04 2011-08-09 Teva Pharmaceutical Industries Ltd. Pharmaceutical composition containing irbesartan
WO2006009736A1 (en) * 2004-06-17 2006-01-26 Wyeth Processes for preparing gonadotropin releasing hormone receptor antagonists
WO2006009734A1 (en) 2004-06-17 2006-01-26 Wyeth Gonadotropin releasing hormone receptor antagonists
CN101048383A (zh) * 2004-11-23 2007-10-03 惠氏公司 促性腺激素释放激素受体拮抗剂
US7582634B2 (en) 2005-02-18 2009-09-01 Wyeth 7-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor
US7534796B2 (en) 2005-02-18 2009-05-19 Wyeth Imidazo[4,5-b]pyridine antagonists of gonadotropin releasing hormone receptor
US7538113B2 (en) 2005-02-18 2009-05-26 Wyeth 4-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor
US20060189619A1 (en) * 2005-02-24 2006-08-24 Wyeth 3-({4-[2-(4-Tert-butylphenyl)-1h-benzimidazol-4-yl]piperazin-1-yl}methyl)pyrido[2,3-b]]pyrazi ne compounds
US7531542B2 (en) 2005-05-18 2009-05-12 Wyeth Benzooxazole and benzothiazole antagonists of gonadotropin releasing hormone receptor
US7582636B2 (en) * 2005-05-26 2009-09-01 Wyeth Piperazinylimidazopyridine and piperazinyltriazolopyridine antagonists of Gonadotropin Releasing Hormone receptor
US20070015689A1 (en) * 2005-06-23 2007-01-18 Alza Corporation Complexation of metal ions with polypeptides
US8945598B2 (en) * 2005-12-29 2015-02-03 Cordis Corporation Low temperature drying methods for forming drug-containing polymeric compositions
US20070160672A1 (en) * 2006-01-06 2007-07-12 Vipul Bhupendra Dave Methods of making bioabsorbable drug delivery devices comprised of solvent cast films
US20070158880A1 (en) * 2006-01-06 2007-07-12 Vipul Bhupendra Dave Methods of making bioabsorbable drug delivery devices comprised of solvent cast tubes
US9458444B2 (en) 2006-02-03 2016-10-04 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
US8476234B2 (en) * 2006-02-03 2013-07-02 Prolor Biotech Inc. Long-acting coagulation factors and methods of producing same
US9249407B2 (en) 2006-02-03 2016-02-02 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
WO2007092252A2 (en) 2006-02-03 2007-08-16 Modigene Inc Long-acting polypeptides and methods of producing same
US8304386B2 (en) * 2006-02-03 2012-11-06 Prolor Biotech, Inc. Long-acting growth hormone and methods of producing same
US8048848B2 (en) 2006-02-03 2011-11-01 Prolor Biotech Ltd. Long-acting interferons and derivatives thereof and methods thereof
US10221228B2 (en) 2006-02-03 2019-03-05 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US8450269B2 (en) 2006-02-03 2013-05-28 Prolor Biotech Ltd. Long-acting growth hormone and methods of producing same
US20140113860A1 (en) 2006-02-03 2014-04-24 Prolor Biotech Ltd. Long-acting polypeptides and methods of producing and administering same
US8759292B2 (en) 2006-02-03 2014-06-24 Prolor Biotech, Llc Long-acting coagulation factors and methods of producing same
US8048849B2 (en) 2006-02-03 2011-11-01 Modigene, Inc. Long-acting polypeptides and methods of producing same
US8946155B2 (en) 2006-02-03 2015-02-03 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US20150038413A1 (en) 2006-02-03 2015-02-05 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US10351615B2 (en) 2006-02-03 2019-07-16 Opko Biologics Ltd. Methods of treatment with long-acting growth hormone
US8207236B2 (en) * 2006-05-23 2012-06-26 Ferro Corporation Method for the production of porous particles
US20080166436A1 (en) * 2007-01-10 2008-07-10 Apperon Inc. Composition for normalizing otitis externa in mammals
WO2008084504A2 (en) * 2007-01-12 2008-07-17 Rubicon Research Private Limited Pharmaceutical compositions of angiotensin ii receptor blockers
US11039707B2 (en) * 2007-05-17 2021-06-22 International Flavors & Fragrances Inc. Microencapsulated delivery system
US20090095164A1 (en) * 2007-05-17 2009-04-16 Salvatore Albert Celeste Method of enhancing beverages by means of a unique microencapsulated delivery system
WO2008156356A1 (en) * 2007-06-19 2008-12-24 Feyecon Development & Implementation B.V. Preparation of a pharmaceutically active ingredient comprising a desolventising step
CA2730760A1 (en) * 2008-07-16 2010-01-21 Surmodics Pharmaceuticals, Inc. Process for preparing microparticles containing bioactive peptides
GB0907251D0 (en) * 2009-04-28 2009-06-10 Univ Leiden Coplymers
US9663778B2 (en) 2009-07-09 2017-05-30 OPKO Biologies Ltd. Long-acting coagulation factors and methods of producing same
US12203113B2 (en) 2009-07-09 2025-01-21 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
UY33127A (es) * 2009-12-22 2011-07-29 Takeda Pharmaceutical Formulación de liberación sostenida
JP2012184364A (ja) * 2011-03-07 2012-09-27 Seiko Instruments Inc アクリル樹脂およびその製造方法
CA2848331C (en) 2011-09-18 2020-07-21 Bio Plasmar Ltd Bio-degradable compositions and use thereof
JP6068787B2 (ja) * 2011-09-30 2017-01-25 大王製紙株式会社 ティシュペーパーの製造方法
US9522945B2 (en) 2012-04-19 2016-12-20 Opko Biologics Ltd. Long-acting oxyntomodulin variants and methods of producing same
EP2727584A1 (de) * 2012-10-31 2014-05-07 Takeda GmbH Abgase zur Verwendung beim Trocknen, Lagern bzw. Rekonstituieren von Biomolekülen
SG10202010383YA (en) 2012-11-20 2020-11-27 Opko Biologics Ltd Method of increasing the hydrodynamic volume of polypeptides by attaching to gonadotrophin carboxy terminal peptides
US20150158926A1 (en) 2013-10-21 2015-06-11 Opko Biologics, Ltd. Long-acting polypeptides and methods of producing and administering same
EA201791275A1 (ru) 2014-12-10 2017-12-29 Опко Байолоджикс Лтд. Способы получения ctp-модифицированных полипептидов длительного действия
IL301728A (en) 2015-06-19 2023-05-01 Opko Biologics Ltd Long-term coagulation factors and methods for their preparation
JP2017190424A (ja) * 2016-04-15 2017-10-19 竹本油脂株式会社 ビニル共重合体
EP3450498B1 (de) * 2016-04-27 2023-01-11 Kuraray Co., Ltd. Acrylische thermoplastische harzzusammensetzung, formartikel, film und verfahren zur herstellung davon und laminat
HUE064463T2 (hu) 2016-07-11 2024-03-28 Opko Biologics Ltd Hosszantartó hatású VII. koagulációs faktor és az elõállítására vonatkozó eljárások
FR3068977B1 (fr) * 2017-07-12 2020-09-04 Arkema France Composition comprenant un polymere a phases multiples et un polymere (meth)acrylique, son procede de preparation et son utilisation
EP3502180A1 (de) * 2017-12-19 2019-06-26 Chi Mei Corporation Polymethacrylatzusammensetzung und daraus hergestellte optische vorrichtung sowie anzeigevorrichtung
EP3882314A4 (de) * 2018-11-15 2022-03-16 Mitsubishi Chemical Corporation Leitfähige zusammensetzung und verfahren zu ihrer herstellung sowie leiter und verfahren zu ihrer herstellung
CN113227249B (zh) 2018-12-27 2024-03-15 株式会社钟化 树脂组合物及其应用
WO2020196921A1 (ja) 2019-03-28 2020-10-01 株式会社カネカ 樹脂組成物の製造方法および樹脂組成物
WO2020196919A1 (ja) * 2019-03-28 2020-10-01 株式会社カネカ 粉粒体およびその利用
JP2023113400A (ja) * 2022-02-03 2023-08-16 株式会社クラレ ポリアミド系樹脂、ポリアミド系樹脂組成物、及び成形品

Family Cites Families (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS528375B2 (de) 1973-07-02 1977-03-09
US4093574A (en) 1977-02-02 1978-06-06 Eli Lilly And Company Somatostatin analogs and intermediates thereto
US4087390A (en) 1977-02-02 1978-05-02 Eli Lilly And Company Somatostatin analogs and intermediates thereto
JPS5944308B2 (ja) 1976-03-23 1984-10-29 武田薬品工業株式会社 ペプタイド
US4100117A (en) 1977-04-21 1978-07-11 Eli Lilly And Company Somatostatin analogs and intermediates thereto
US4253998A (en) 1979-03-09 1981-03-03 American Home Products Corporation Peptides related to somatostatin
JPS54148722A (en) 1978-05-12 1979-11-21 Takeda Chem Ind Ltd Nonapeptide and its preparation
US4277394A (en) 1979-04-23 1981-07-07 Takeda Chemical Industries, Ltd Tetrapeptidehydrazide derivatives
US4342832A (en) 1979-07-05 1982-08-03 Genentech, Inc. Method of constructing a replicable cloning vehicle having quasi-synthetic genes
JPS5692846A (en) 1979-12-27 1981-07-27 Takeda Chem Ind Ltd Tetrapeptide derivative and its preparation
US4675189A (en) 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
JPH0678425B2 (ja) 1984-07-06 1994-10-05 和光純薬工業株式会社 重合体の新規製造法
US5120712A (en) 1986-05-05 1992-06-09 The General Hospital Corporation Insulinotropic hormone
JP2583257B2 (ja) 1986-05-05 1997-02-19 ザ・ジェネラル・ホスピタル・コーポレーション インシュリン向性ホルモン
US5118666A (en) 1986-05-05 1992-06-02 The General Hospital Corporation Insulinotropic hormone
US5614492A (en) 1986-05-05 1997-03-25 The General Hospital Corporation Insulinotropic hormone GLP-1 (7-36) and uses thereof
AU615966B2 (en) * 1987-12-04 1991-10-17 Takeda Chemical Industries Ltd. Crystals of cephem hydrochloride
JP2861267B2 (ja) 1989-06-01 1999-02-24 萬有製薬株式会社 生理活性物質ｂｅ―１８２５７類
US5232707A (en) * 1989-07-10 1993-08-03 Syntex (U.S.A.) Inc. Solvent extraction process
CA2020755A1 (en) 1989-07-10 1991-01-11 David M. Lokensgard Solvent extraction process
DK0412053T3 (da) * 1989-07-31 1995-07-10 Ciba Geigy Ag Ekstraktion af organiske opløsningsmidler fra formede genstande med superkritiske fluida og gasser nær det kritiske punkt
GB8919726D0 (en) 1989-08-31 1989-10-11 Fujisawa Pharmaceutical Co Ws7338 substances and preparation thereof
IL95975A (en) 1989-10-24 1997-06-10 Takeda Chemical Industries Ltd N-benzyl- 2-alkylbenzimidazole derivatives, their production and pharmaceutical compositions containing them
CA2032559C (en) 1989-12-28 2001-11-06 Kiyofumi Ishikawa Endothelin antagonistic cyclic pentapeptides
ATE164852T1 (de) 1990-01-24 1998-04-15 Douglas I Buckley Glp-1-analoga verwendbar in der diabetesbehandlung
US5545618A (en) 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
US5196444A (en) 1990-04-27 1993-03-23 Takeda Chemical Industries, Ltd. 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof
US5284828A (en) 1990-05-14 1994-02-08 Fujisawa Pharmaceutical Co. Ltd. Peptide compound and its preparation
CA2059380A1 (en) 1991-01-24 1992-07-25 Yiu-Kuen T. Lam Endothelin receptor antagonists isolated from microbispora
IL102183A (en) 1991-06-27 1999-11-30 Takeda Chemical Industries Ltd Biphenyl substituted heterocyclic compounds their production and pharmaceutical compositions comprising them
US5312958A (en) 1992-01-31 1994-05-17 Takeda Chemical Industries, Ltd. Process for producing 4-bromomethylbiphenyl compounds
SK155694A3 (en) 1992-06-15 1995-05-10 Pfizer Glucagon-like peptide, insulinotropin derivatives, method of their preparation, pharmaceutical agent containing and using these matters
US5484955A (en) 1992-07-06 1996-01-16 Takeda Chemical Industries, Ltd. Tri-higher alkyl tin azide and its use
JPH0680584A (ja) 1992-07-13 1994-03-22 Nisshin Flour Milling Co Ltd グリセンチンを有効成分とする医薬
TW333456B (en) 1992-12-07 1998-06-11 Takeda Pharm Ind Co Ltd A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide.
NZ250844A (en) 1993-04-07 1996-03-26 Pfizer Treatment of non-insulin dependant diabetes with peptides; composition
US5424286A (en) 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
AU7531094A (en) 1993-08-24 1995-03-21 Novo Nordisk A/S Protracted glp-1
JPH07101877A (ja) 1993-10-04 1995-04-18 Mitsui Toatsu Chem Inc 血小板減少症治療剤
US6280771B1 (en) * 1997-02-20 2001-08-28 Therics, Inc. Dosage forms exhibiting multi-phasic release kinetics and methods of manufacture thereof
CA2137206A1 (en) 1993-12-09 1995-06-10 John A. Galloway Glucagon-like insulinotropic peptides, compositions and methods
US5705483A (en) 1993-12-09 1998-01-06 Eli Lilly And Company Glucagon-like insulinotropic peptides, compositions and methods
CA2178592C (en) * 1993-12-09 2009-07-28 Zentaris Gmbh Long-acting injection suspensions and a process for their preparation
DE69517832T2 (de) 1994-01-28 2000-11-09 Takeda Chemical Industries, Ltd. Ein Verfahren zur Herstellung von Tetrazolyl-Verbindungen
US5574008A (en) 1994-08-30 1996-11-12 Eli Lilly And Company Biologically active fragments of glucagon-like insulinotropic peptide
JP3862304B2 (ja) 1994-09-09 2006-12-27 武田薬品工業株式会社 徐放性製剤
DE69519382T3 (de) 1994-09-09 2008-09-18 Takeda Pharmaceutical Co. Ltd. Zubereitung mit verzögerter freigabe eines metallsalz eines peptids
US5512549A (en) 1994-10-18 1996-04-30 Eli Lilly And Company Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
WO1996020005A1 (en) 1994-12-23 1996-07-04 Novo Nordisk A/S Protracted glp-1 compositions
US20010006943A1 (en) 1994-12-23 2001-07-05 Ejvind Jensen Protracted GLP-1 compositions
WO1997001331A2 (en) 1995-06-27 1997-01-16 Takeda Chemical Industries, Ltd. Method of producing sustained-release preparation
DE19530865A1 (de) 1995-08-22 1997-02-27 Michael Dr Med Nauck Wirkstoff sowie Mittel zur parenteralen Ernährung
TW448055B (en) 1995-09-04 2001-08-01 Takeda Chemical Industries Ltd Method of production of sustained-release preparation
JP3902272B2 (ja) 1995-09-04 2007-04-04 武田薬品工業株式会社 徐放性製剤の製造法
US5766620A (en) 1995-10-23 1998-06-16 Theratech, Inc. Buccal delivery of glucagon-like insulinotropic peptides
US5849322A (en) 1995-10-23 1998-12-15 Theratech, Inc. Compositions and methods for buccal delivery of pharmaceutical agents
CA2192782C (en) * 1995-12-15 2008-10-14 Nobuyuki Takechi Production of microspheres
JPH10265404A (ja) 1996-02-02 1998-10-06 Mitsui Chem Inc ヒト成長ホルモンを含有する医薬製剤
DK1975177T3 (da) 1996-03-01 2011-07-25 Novo Nordisk As Appetitundertrykkende peptid, formuleringer dermed og anvendelse deraf
JP3149958B2 (ja) 1996-08-30 2001-03-26 ノボ ノルディスク アクティーゼルスカブ Ｇｌｐ―１誘導体
US6268343B1 (en) 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
US6458924B2 (en) 1996-08-30 2002-10-01 Novo Nordisk A/S Derivatives of GLP-1 analogs
US5766637A (en) * 1996-10-08 1998-06-16 University Of Delaware Microencapsulation process using supercritical fluids
UA65549C2 (uk) 1996-11-05 2004-04-15 Елі Ліллі Енд Компані Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
JP4459315B2 (ja) 1996-12-20 2010-04-28 武田薬品工業株式会社 徐放性製剤の製造法
WO1998043658A1 (en) 1997-03-31 1998-10-08 Eli Lilly And Company Glucagon-like peptide-1 analogs
JP2002510193A (ja) 1997-03-31 2002-04-02 イーライ・リリー・アンド・カンパニー グルカゴン様ペプチド−１類似体
CN1269805A (zh) 1997-07-14 2000-10-11 博尔德生物技术公司 生长激素和相关蛋白的衍生物
US6391452B1 (en) * 1997-07-18 2002-05-21 Bayer Corporation Compositions for nasal drug delivery, methods of making same, and methods of removing residual solvent from pharmaceutical preparations
DK1019077T4 (da) 1997-08-08 2011-03-07 Amylin Pharmaceuticals Inc Hidtil ukendte exendinagonistforbindelser
CA2312190A1 (en) 1997-12-05 1999-06-17 Eli Lilly And Company Glp-1 formulations
AU2610899A (en) 1998-02-27 1999-09-15 Novo Nordisk A/S N-terminally modified glp-1 derivatives
WO1999043705A1 (en) 1998-02-27 1999-09-02 Novo Nordisk A/S N-terminally truncated glp-1 derivatives
WO1999043708A1 (en) 1998-02-27 1999-09-02 Novo Nordisk A/S Glp-1 derivatives of glp-1 and exendin with protracted profile of action
JP2002504518A (ja) 1998-02-27 2002-02-12 ノボ ノルディスク アクティーゼルスカブ 部分的に構造化されたミセルー様凝集体を形成する、２５％を超えるヘリックス−含有率を有するｇｌｐ−１誘導体
WO1999043706A1 (en) 1998-02-27 1999-09-02 Novo Nordisk A/S Derivatives of glp-1 analogs
US6613358B2 (en) * 1998-03-18 2003-09-02 Theodore W. Randolph Sustained-release composition including amorphous polymer
JP4758525B2 (ja) 1998-03-20 2011-08-31 武田薬品工業株式会社 生理活性ポリペプチドの徐放性製剤およびその製造法
DE69904701T2 (de) 1998-03-20 2003-11-06 Takeda Chemical Industries, Ltd. Physiologisch aktives polypeptid enthaltende zubereitung mit verzögerter freisetzung und deren herstellung
EP2311436A1 (de) 1998-04-27 2011-04-20 Altus Pharmaceuticals Inc. Stabilisierte Protein-Kristalle, diese enthaltende Formulierungen und ihre Herstellungsverfahren
CA2270320A1 (en) 1998-04-28 1999-10-28 Patricia Lee Brubaker Novel microsphere composition
NZ508823A (en) 1998-06-12 2003-10-31 Amylin Pharmaceuticals Inc Glucagon-like peptide-1 improves beta-cell response to glucose in subjects with impaired glucose tolerance or increased risk of a cardiovascular or cerebrovascular event
JP4624558B2 (ja) 1998-08-10 2011-02-02 ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ， アズ レプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ ＧＬＰ−１またはＥｘｅｎｄｉｎ−４による、非インスリン産生細胞のインスリン産生細胞への分化、およびその使用
US6284725B1 (en) 1998-10-08 2001-09-04 Bionebraska, Inc. Metabolic intervention with GLP-1 to improve the function of ischemic and reperfused tissue
US6429197B1 (en) 1998-10-08 2002-08-06 Bionebraska, Inc. Metabolic intervention with GLP-1 or its biologically active analogues to improve the function of the ischemic and reperfused brain
JP4486187B2 (ja) 1998-10-27 2010-06-23 武田薬品工業株式会社 新規ｇ蛋白質共役型レセプター蛋白質、そのｄｎａおよびそのリガンド
US6403672B1 (en) * 1998-11-30 2002-06-11 University Technology Corporation Preparation and use of photopolymerized microparticles
PL205713B1 (pl) 1998-12-07 2010-05-31 Sod Conseils Rech Applic Związki stanowiące analogi GLP-1, kompozycje farmaceutyczne zawierające takie związki oraz zastosowanie tych związków
WO2000034331A2 (en) 1998-12-07 2000-06-15 Societe De Conseils De Recherches Et D'applications Scientifiques Sas Analogues of glp-1
CA2358107C (en) 1998-12-22 2011-08-23 Eli Lilly And Company Shelf-stable formulation of glucagon-like peptide-1
CN101181236A (zh) 1999-01-14 2008-05-21 安米林药品公司 新型exendin激动剂制剂及其给药方法
EP1175443A1 (de) 1999-04-30 2002-01-30 Amylin Pharmaceuticals, Inc. Modifizierte exendine und exendin agonisten
US6344180B1 (en) 1999-06-15 2002-02-05 Bionebraska, Inc. GLP-1 as a diagnostic test to determine β-cell function and the presence of the condition of IGT and type II diabetes
US6660716B1 (en) 1999-06-21 2003-12-09 Eli Lilly And Company Method for treating non-insulin dependent diabetes using thiazolidinediones with glucagon-like peptide-1 and agonists thereof
IT1318404B1 (it) * 2000-03-17 2003-08-25 Eurand Int Processo per la preparazione di formulazioni a rilascio accelerato conimpiego di fluidi compressi.
US6620351B2 (en) * 2000-05-24 2003-09-16 Auburn University Method of forming nanoparticles and microparticles of controllable size using supercritical fluids with enhanced mass transfer
US6967028B2 (en) * 2000-07-31 2005-11-22 Mainelab Prolonged release microspheres for injectable administration
WO2002074340A1 (fr) * 2001-03-16 2002-09-26 Takeda Chemical Industries, Ltd. Procede de fabrication d'une preparation a liberation continue
US20030072716A1 (en) * 2001-06-22 2003-04-17 Raveendran Poovathinthodiyil Renewable, carbohydrate based CO2-philes

Also Published As

Publication number Publication date
CA2430934C (en) 2011-06-21
EP1346722B1 (de) 2008-12-10
EP2062593A3 (de) 2011-08-17
US20060241045A1 (en) 2006-10-26
EP1346722A1 (de) 2003-09-24
CA2430934A1 (en) 2002-06-06
US7090869B2 (en) 2006-08-15
EP2062593A2 (de) 2009-05-27
WO2002043709A1 (fr) 2002-06-06
US20040018240A1 (en) 2004-01-29
AU2002224124A1 (en) 2002-06-11
EP1346722A4 (de) 2005-08-03
DE60136958D1 (de) 2009-01-22
JP2009062389A (ja) 2009-03-26

Similar Documents

Publication Publication Date Title
DE60136958D1 (de) Verfahren zur herstellung einer zubereitung mit einer bioaktiven substanz
DE60144104D1 (de) Membranen mit gemischter matrix und pyrolisierten kohlenstoffsiebteilchen und verfahren zur herstellung derselben
ATE426575T1 (de) Peptidenanostrukturen die fremdmaterial enthalten,und verfahren zur herstellung derselben
DE69420632D1 (de) Verfahren zur Herstellung von Arzneizubereitungen mit verzögerter Wirkstoffabgabe
DE69500992D1 (de) WäSSRIGES POLYURETHANPOLYMER, TRENNBESCHICHTUNG, KLEBEFILM UND VERFAHREN ZUR HERSTELLUNG
DE60329298D1 (de) Polymerisierbare zusammensetzung, die zusammensetzung enthaltendes optisches material und verfahren zur herstellung des materials
ATE508725T1 (de) Verfahren zur herstellung von tabletten
DE60116810D1 (de) Polyhydroxyalkanoat enthaltend 3-Hydroxythienyl-Alkansäure als Monomer und ein Verfahren zur Herstellung desselben
DE60036560D1 (de) Fluorkohlenstoff-polymerzusammensetzungen mit hydrophilen funktionellen gruppen und verfahren zur herstellung davon
DE60119282D1 (de) Verfahren zur herstellung von sehr reinen fluoropolymeren
DE60121340D1 (de) Verfahren zur herstellung eines photochromen formteils
ATE189017T1 (de) Verfahren zur herstellung einer materialbahn
DE50107512D1 (de) Verfahren zur herstellung vernetzter kautschukpartikel
DE50207803D1 (de) Verfahren zur herstellung gesättigter alkohole, ketone, aldehyde und carbonsäuren
DE60227630D1 (de) Verfahren zur Herstellung von Fullerene
DE60207154D1 (de) Verfahren zur Herstellung amphoteren Polyurethanharzes, sowie daraus erhaltenes amphoteres Polyurethanharz und Harzzusammensetzung
DE50103605D1 (de) Verfahren zur Herstellung eines Spritzlings für pharmazeutische Anwendungen
ATE506083T1 (de) Verfahren zur herstellung bioabsorbierbarer wirkstofffreisetzungsvorrichtungen aus lösungsmittelgegossenen röhren
DE60030183D1 (de) Verfahren zur Herstellung einer Membranvorrichtung mit interner Spülung
DE60122725D1 (de) Organosiliciumverbindungen die polyorganosiloxane mit ethylenisch ungesättigten durch imidgruppen aktivierte gruppen enthalten und verfahren zur deren herstellung
DE69008122D1 (de) Phenolnovolakharz, dessen härtungsprodukt und verfahren zur herstellung.
DE60119914D1 (de) Verfahren zur herstellung von zusammensetzungen mit beschleunigter abgabe unter verwendung von komprimierten fluiden
DE59310184D1 (de) Verfahren zur herstellung dünnflüssiger, lagerstabiler amphotenside
DE60002686D1 (de) Verfahren zur entformung eines durchsichtigen gegenstandes und dessen anwendung zur herstellung eines gegenstandes aus durchsichtigem kunststoff wie z.b. einer kontaktlinse
DE60035130D1 (de) Verfahren zur Herstellung eines photochromen, gehärteten Produkts

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties